

Challenge met with innovation.

Wareham Development is privileged to work with many of the Bay Area's remarkable innovators, who have accomplished much during these challenging times. We salute all of our tenants in the biotech and greentech sectors on inspiring achievements in 2010 to date including these East Bay scientists:

Dr. Jay Keasling was elected to the National Academy of Engineering, which is among the highest professional distinctions accorded to an engineer. A research collaboration led by Dr. Keasling with the U.S. Department of Energy's **Joint BioEnergy Institute** has developed a microbe that can produce an advanced biofuel directly from biomass. Deploying the tools of synthetic biology, JBEI researchers have engineered a strain of Escherichia coli (E. coli) bacteria to produce biodiesel fuel and other important chemicals derived from fatty acids.

Dr. Mina Bissell, Distinguished Scientist with the U.S. Department of Energy's **Lawrence Berkeley National Laboratory (Berkeley Lab)** has been elected to the National Academy of Sciences (NAS), one of the nation's highest honors for a scientist. A colleague, renowned cancer researcher **Dr. Joe Gray** and Berkeley Lab will receive about \$13.5 million over five years from the National Cancer Institute to develop computational models that predict breast cancer responses to therapeutic agents.

Lawrence Berkeley National Laboratory is credited with boosting the San Francisco Bay Area economy by 5,600 jobs and \$690 million last year, according to a recently published study.

XOMA, Ltd. has been issued two new U.S. patents for methods of Treating Type 2 Diabetes and inflammatory diseases using Interleukin-1 beta antibodies. Xoma also received a \$1 million milestone payment from Takeda Pharmaceutical.

Temasek Holdings has invested \$47.8 million into **Amyris Biotechnologies**, which has also established a joint venture with Grupo São Martinho, one of the largest sugar and ethanol producers in Brazil, to produce Amyris renewable products.

Dynavax Technologies Corp. announced that its two Phase 3 Hepatitis B trials have been cleared by the DSMB to continue immunizations. Dynavax will receive \$4 million from Merck to cover the cost of the Hepatitis B program.

Bionovo, Inc. announced the patent issuance for Bezielle® (BZL101) for metastatic breast cancer.

NovaBay Pharmaceuticals, Inc. has received \$3.75 million in milestone payments from partner Galderma S.A., and reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria.

Zogenix, Inc. announced the U.S. commercial launch of SUMAVEL™ DosePro™ (sumatriptan injection) needle-free delivery system and also that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen for the treatment of moderate to severe pain in individuals requiring round-the-clock treatment.

Sangamo BioSciences, Inc. announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of \$3 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International.

The Bill & Melinda Gates Foundation awarded \$5 million to the Catalysis Foundation for Health, a nonprofit organization founded by **Tethys Bioscience** CEO Mickey Urdea that will use the money to discover new tuberculosis biomarkers and more effective TB treatments. Tethys raised \$25 million in Series D funding to be used to expand commercialization of its proprietary PreDx™ Diabetes Risk Score (DRS) product.

The cold hit program of the **California Department of Justice DNA Forensic Lab** has allowed local law enforcement agencies to clear their DNA evidence backlog of over 13,000 unsolved cases and propelled the number of "hits" from one a year to an average of one a day.



WAREHAM
DEVELOPMENT

Building the San Francisco Bay Area Biotech Corridor since 1977
for Noble and Nobel Scientists